INS and type 2 diabetes mellitus: In type 2 diabetes, accumulating evidences from randomized clinical trials supports the efficacy of once-weekly icodec and efsitora, showing non-inferiority—and in some cases, superiority—compared to once-daily basal insulin, both in insulin-naïve individuals and in those previously treated with insulin.